Nutraceuticals May Treat Negative Symptoms of Schizophrenia Nutraceuticals May Treat Negative Symptoms of Schizophrenia

New randomized control trials show signs of the potential benefit of herbal and nutraceutical agents as adjunctive treatment for the negative symptoms of schizophrenia.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Source Type: news

Related Links:

Publication date: Available online 17 May 2019Source: Respiratory Medicine Case ReportsAuthor(s): Yazan Zayed, Danielle Osterholzer, Emily Armstrong, Qazi Azher, Ghassan BachuwaAbstractA 57-year-old male with schizophrenia and a 37 pack-year smoking history presented with cough productive of purulent sputum associated with hemoptysis and worsening shortness of breath. Computed tomography (CT) scan revealed multiple masses in the right upper and lower lobes with a small distal tracheal mass and significant mediastinal lymphadenopathy. CT guided biopsy of the largest lung mass in the right lower lobe confirmed a diagnosis of...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
DiscussionBaseline P3a ERP, and PANSS general score were significant and independent predictors of later MCAS functioning at 12-month. Overall, individuals with worse functioning and greater symptomology produced smaller amplitudes. Our results highlight the heterogeneity within the FEP population. Correlation patterns among ERPs are similar between patients and controls. P3a and P3b amplitudes appear to link with higher-order cognitive and psychosocial functioning.
Source: International Journal of Psychophysiology - Category: Psychiatry & Psychology Source Type: research
CONCLUSION: Risperidone loaded chitosan nanoparticles were effective against schizophrenia via intranasal route. PMID: 31094571 [PubMed - as supplied by publisher]
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Publication date: Available online 16 May 2019Source: Journal of Psychiatric ResearchAuthor(s): Emma L. Hawkins, Roxanne D. Hawkins, Martin Dennis, Joanne M. Williams, Stephen M. LawrieAbstractAnimal-assisted therapy (AAT) is increasingly researched as a potential treatment for physical and mental illness, including schizophrenia. The aim of the current paper is to systematically review randomised controlled trials (RCTs) to assess the effectiveness of AAT for schizophrenia and related disorders. We searched PubMed, PsycINFO, CINAHL, EMBASE, The Cochrane Library, CAB Abstracts, and Web of Science for RCTs of AAT for schizo...
Source: Journal of Psychiatric Research - Category: Psychiatry Source Type: research
Authors: Breadon C, Kulkarni J Abstract INTRODUCTION: Women with schizophrenia and their babies are at high risk of adverse outcomes in pregnancy and childbirth. A better understanding of the specific risks conferred by the illness itself and by the treatment provided will help guide more effective care of these women. Areas covered: Herein, the authors review genetic, demographic, socioeconomic, nutritional and lifestyle risks associated with schizophrenia in pregnancy. They also cover specific risks associated with typical antipsychotic medications, specific risks associated with atypical antipsychotic medication...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Publication date: Available online 16 May 2019Source: Neuroscience LettersAuthor(s): Samaneh Ghotbi Ravandi, Mohammad Shabani, Hamideh Bashiri, Monavvar Saeedi Goraghani, Mehdi Khodamoradi, Masoumeh NozariAbstractNeonatal administration of MK-801 (NMDA receptor antagonist) results in schizophrenia-like behaviors in rodents. Berberine (BBR) is a herbal alkaloid, which shows many neuroprotective properties in neurodegenerative diseases. The present study was designed to clarify whether systemic administration of BBR improves motor and cognitive disturbances induced by MK-801 treatment. Male Wistar rat pups were treated with ...
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
Schizophrenia is a phenotypically heterogeneous and poorly understood disorder. While its etiology is likely multifactorial, immune system dysfunction has increasingly been implicated in its development. As hallucinations and delusions occur frequently and prominently in autoimmune encephalitis (AE), numerous studies have sought to determine whether a small subset of individuals diagnosed with schizophrenia possess anti-neuronal antibodies implicated in AE. Exploring this possibility is of clinical relevance, as identifying individuals with AE who have been misdiagnosed as having a primary psychotic disorder may allow for ...
Source: Neuropsychobiology - Category: Psychiatry & Psychology Source Type: research
Contributors : Tracy A O'Mara ; Dylan M Glubb ; Amanda B SpurdleSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensDNA regulatory elements are reported to be enriched for variants identified by genome-wide association studies to be significantly assocaited with risk of complext traits. Here, we have performed genome-wide mapping of histone modifications in two endometrial cancer cell lines and performed interestions of these sites with genetic risk variants identified by genome-wide association study of endometrial cancer. Histone modifications indicative of enhancers (H3K4...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
Conclusion: Paliperidone has some dynamic and kinetic superiority to the parent drug risperidone. Nonetheless, larger rigorous studies would define the real place of the atypical antipsychotic paliperidone in child and adolescent psychiatry. Until then, risperidone with its long track record in CAP population would remain a first option though.Pharmacology 2019;104:67 –70
Source: Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: September 2019Source: Schizophrenia Research: Cognition, Volume 17Author(s): Philip D. Harvey, Mackenzie Taylor Jones
Source: Schizophrenia Research: Cognition - Category: Psychiatry Source Type: research
More News: Complementary Medicine | Health | Herbs | Psychiatry | Schizophrenia